At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 42 enrolled
Drug / intervention
Placebo +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2a Study to Evaluate the Safety and Efficacy of Namilumab in Subjects With Moderate-to-severely Active Axial Spondyloarthritis
In Brief
A Phase 2 clinical trial evaluating Placebo and Namilumab for Axial Spondyloarthritis. Completed, enrolled 42 participants across 9 sites.
Detailed Summary
The study will assess the effect of namilumab, a GM-CSF inhibitor, on the clinical response in subjects with axial spondyloarthritis. Subjects will receive treatment with either namilumab or placebo.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAxial Spondyloarthritis
CountriesUnited Kingdom
CollaboratorsIQVIA Pty Ltd, Innovate UK
Timeline
Phase 2CompletedFinished
20192020202120222023202420252026
First PostedAug 2018
Enrollment StartSep 2018
Primary CompletionFeb 2020
TodayJul 2026
First PostedAug 9, 2018
Enrollment StartSep 6, 2018
Primary CompletionFeb 4, 2020
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 7.9 years ago
Interventions
Placebobiological
Placebo solution for subcutaneous injection.
Namilumabbiological
Namilumab solution for subcutaneous injection